Salubrity Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Revenue 97.28%
(FY 2020)
- Profit 24.48%
(FY 2020)
- Ebitda -282.21%
(FY 2020)
- Net Worth -75.36%
(FY 2020)
- Total Assets 247.75%
(FY 2020)
About Salubrity Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kamal Anand and Pankhuri Priya serve as directors at the Company.
- CIN/LLPIN
U51101DL2015PTC279582
- Company No.
279582
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 2015
- Date of AGM
29 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Salubrity Pharma Private Limited offer?
Salubrity Pharma Private Limited offers a wide range of products and services, including Ayurvedic, Herbal Oils and Cosmetics, Herbal Cosmetics.
Who are the key members and board of directors at Salubrity Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Anand  | Director | 28-Apr-2015 | Current |
| Pankhuri Priya | Director | 28-Apr-2015 | Current |
Financial Performance of Salubrity Pharma.
Salubrity Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 97.28% increase. The company also saw a substantial improvement in profitability, with a 24.48% increase in profit. The company's net worth observed a substantial decline by a decrease of 75.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Salubrity Pharma?
In 2020, Salubrity Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Gratitude Exim Private LimitedActive 11 years 7 months
Kamal Anand and Pankhuri Priya are mutual person
- Bingo Manufacturing And Marketing Private LimitedActive 11 years 6 months
Kamal Anand and Pankhuri Priya are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Salubrity Pharma?
Unlock and access historical data on people associated with Salubrity Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Salubrity Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Salubrity Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
